Inspire Hopes For Diquafosol Approval In 2005
This article was originally published in The Pink Sheet Daily
You may also be interested in...
SEC Eyes Trading Around Inspire's Announcement Of Failed Diquafosol Study
A drop in the firm's stock on the morning that unsuccessful Phase III trial results for diquafosol tetrasodium were announced prompts a formal investigation by the Securities & Exchange Commission.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.